Fundraising FoxSofinnova Partners — 2016 Investments
5 investments dated 2016 · listed companies and verified rows first · show all
MaxCyte develops non-viral electroporation and cell-engineering technology used to transfect and engineer cells for research and therapeutic development.
BiotechDeep TechMedical DevicesGaithersburg, US
Douglas A. Doerfler(Executive Officer, Director)Madhusudan V Peshwa(Executive Officer)Ronald E. Holtz(Executive Officer, Director)Thomas Ross(Executive Officer)Karen Donato(Executive Officer)
BoardWilliam Brooke(Director)
RefleXion Medical develops SCINTIX autonomous radiotherapy, an external beam theranostic oncology platform that uses biological signals from radiopharmaceutical-labeled cancer cells to deliver real-time, motion-managed radiation to lung and bone tumors from primary or metastatic disease.
BiotechHealthtechMedical DevicesHayward, US
Samuel Mazin(Executive Officer, Director)inAkshay Nanduri(Executive Officer, Director)in
BoardJay Watkins(Director)in
Board seatAntoine Papiernik· per SEC Form D
Co-investorsAscension VenturesCatalio Capital Management, LPPfizer Venture InvestmentsSonder CapitalVenrock
BiotechNew York, US
Masoud Tavazoie(Chief Scientific Officer)David Darst(Chief Operating Officer)Isabel Kurth(Vice President - Research)
BoardShahram Seyedin-Noor(Executive Chairman)Nancy Chang(Director)
Board seatAntoine Papiernik· per SEC Form D
Co-investors+ND CapitalOceanpine Capital
CelluComp develops sustainable, cellulose-based bio-composite materials for packaging applications, serving consumer goods and packaging companies seeking environmentally responsible alternatives.
Advanced ManufacturingCircular EconomyCleantechNew MaterialsScotland, GB
Dr. Eric Whale(Founder and Head of Technology)Dr. David Hepworth(Founder)Christian Kemp-Griffin(CEO)in
Co-investorsScottish EnterpriseCapagro
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Autolus
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.